Characterization of genome integrity for oversized recombinant AAV vector

Molecular Therapy

Volumn 18, Issue 1, 2010, Pages 87-92

  Dong, Biao ^a   Nakai, Hiroyuki ^b   Xiao, Weidong ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DNA PACKAGING; DNA SEQUENCE; GENE CASSETTE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RESTRICTION MAPPING; SILVER STAINING; SOUTHERN BLOTTING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT;

ANIMALS; CELL LINE; DEPENDOVIRUS; GENETIC VECTORS; GENOME, VIRAL; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 74049092844     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.258     Document Type: Article

References (38)

1. Muzyczka, N and Berns, KI (2002). Parvoviridae: the viruses and their replication. In: Knipe, DM and Howley, PM (eds). Fields Virology, 4th edn. Lippincott Williams & Wilkins: Philadelphia, pp 2327-2360.
2. Ferrari, FK, Xiao, X, McCarty, D and Samulski, RJ (1997). New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med 3: 1295-1297.
3. Samulski, RJ (2003). AAV vectors, the future workhorse of human gene therapy. Ernst Schering Res Found Workshop: 25-40.
4. Herzog, RW, Yang, EY, Couto, LB, Hagstrom, JN, Elwell, D, Fields, PA et al. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 56-63.
5. Fisher, KJ, Jooss, K, Alston, J, Yang, Y, Haecker, SE, High, K et al. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3: 306-312.
6. Li W, Zhang L, Johnson JS, Zhijian W, Grieger JC, Ping-Jie X et al. (2009). Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther (epub ahead of print).
7. Asokan, A and Samulski, RJ (2006). AAV does the shuffe. Nat Biotechnol 24: 158-160.
8. Grimm, D and Kay, MA (2003). From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3: 281-304.
9. Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388.
10. Gao, G P, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859.
11. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and effcacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
12. Hasbrouck, NC and High, KA (2008). AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 15: 870-875.
13. High, KA (2007). Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am Soc Hematol Educ Program: 466-472.
14. Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specifc T cells. Blood 114: 2077-2086.
15. Rodino-Klapac, LR, Lee, JS, Mulligan, RC, Clark, KR and Mendell, JR (2008). Lack of toxicity of α-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 71: 240-247.
16. Hajjar, RJ, Zsebo, K, Deckelbaum, L, Thompson, C, Rudy, J, Yaroshinsky, A et al. (2008). Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 14: 355-367.
17. Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983.
18. Kotin, RM, Siniscalco, M, Samulski, RJ, Zhu, XD, Hunter, L, Laughlin, CA et al. (1990). Site-specifc integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215.
19. Yang, CC, Xiao, X, Zhu, X, Ansardi, DC, Epstein, ND, Frey, MR et al. (1997). Cellular recombination pathways and viral terminal repeat hairpin structures are suffcient for adeno-associated virus integration in vivo and in vitro. J Virol 71: 9231-9247.
20. Nakai, H, Iwaki, Y, Kay, MA and Couto, LB (1999). Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 73: 5438-5447.
21. Nakai, H, Wu, X, Fuess, S, Storm, TA, Munroe, D, Montini, E et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79: 3606-3614.
22. Duan, D, Sharma, P, Yang, J, Yue, Y, Dudus, L, Zhang, Y et al. (1998). Circular intermediates of recombinant adeno-associated virus have defned structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72: 8568-8577.
23. Duan, D, Sharma, P, Dudus, L, Zhang, Y, Sanlioglu, S, Yan, Z et al. (1999). Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol 73: 161-169.
24. Duan, D, Yan, Z, Yue, Y and Engelhardt, JF (1999). Structural analysis of adeno-associated virus transduction circular intermediates. Virology 261: 8-14.
25. Nakai, H, Yant, SR, Storm, TA, Fuess, S, Meuse, L and Kay, MA (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75: 6969-6976.
26. Dong, JY, Fan, PD and Frizzell, RA (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7: 2101-2112.
27. Hermonat, PL, Quirk, JG, Bishop, BM and Han, L (1997). The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett 407: 78-84.
28. Grieger, JC and Samulski, RJ (2005). Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 79: 9933-9944.
29. Wu, J, Zhao, W, Zhong, L, Han, Z, Li, B, Ma, W et al. (2007). Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 18: 171-182.
30. Allocca, M, Doria, M, Petrillo, M, Colella, P, Garcia-Hoyos, M, Gibbs, D et al. (2008). Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 118: 1955-1964.
31. Lu, H, Chen, L, Wang, J, Huack, B, Sarkar, R, Zhou, S et al. (2008). Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther 19: 648-654.
32. Nakai, H, Storm, TA, Fuess, S and Kay, MA (2003). Pathways of removal of free DNA vector ends in normal and DNA-PKcs-defcient SCID mouse hepatocytes transduced with rAAV vectors. Hum Gene Ther 14: 871-881.
33. Inagaki, K, Ma, C, Storm, TA, Kay, MA and Nakai, H (2007). The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 81: 11304-11321.
34. Chen, L, Zhu, F, Li, J, Lu, H, Jiang, H, Sarkar, R et al. (2007). The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther 15: 1856-1862.
35. Cao, L, Liu, Y, During, MJ and Xiao, W (2000). High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 74: 11456-11463.
36. Cao, L, During, M and Xiao, W (2002). Replication competent helper functions for recombinant AAV vector generation. Gene Ther 9: 1199-1206.
37. Samulski, RJ, Srivastava, A, Berns, KI and Muzyczka, N (1983). Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 33: 135-143.
38. Chen, L, Lu, H, Wang, J, Sarkar, R, Yang, X, Wang, H et al. (2009). Enhanced factor VIII heavy chain for gene therapy of hemophilia A. Mol Ther 17: 417-424.